Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BPMC

Blueprint Medicines Corp

Dec 26 • 02:30PM ET

91.36

Dollar change +0.90
Percentage change 0.99	%

Healthcare • Biotechnology • USA • NASD

Peers: INCY EXEL SAGE TXMD GNFT BLUE CARA DNLI BYSI MGNX

| Held by: VTI IWM VB XBI VXF VBK IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	3.11%	Shs Outstand	63.45M	Perf Week	-0.46%
Market Cap	5.80B	Forward P/E	-	EPS next Y	-0.92	Insider Trans	-6.22%	Shs Float	61.55M	Perf Month	-2.68%
Income	-128.05M	PEG	-	EPS next Q	-0.70	Inst Own	102.37%	Short Float	7.36%	Perf Quarter	2.58%
Sales	434.41M	P/S	13.36	EPS this Y	88.32%	Inst Trans	-1.52%	Short Ratio	7.13	Perf Half Y	-15.82%
Book/sh	4.93	P/B	18.51	EPS next Y	5.72%	ROA	-11.11%	Short Interest	4.53M	Perf Year	0.60%
Cash/sh	11.56	P/C	7.90	EPS next 5Y	-	ROE	-49.66%	52W Range	72.24 - 121.90	Perf YTD	-0.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.19%	ROI	-13.80%	52W High	-25.06%	Beta	0.59
Dividend TTM	-	Quick Ratio	3.27	Sales past 5Y	220.20%	Gross Margin	93.83%	52W Low	26.46%	ATR (14)	3.31
Dividend Ex-Date	-	Current Ratio	3.32	EPS Y/Y TTM	77.64%	Oper. Margin	-63.52%	RSI (14)	45.50	Volatility	4.59% 3.33%
Employees	655	Debt/Eq	2.34	Sales Y/Y TTM	100.93%	Profit Margin	-29.48%	Recom	1.71	Target Price	125.58
Option/Short	Yes / Yes	LT Debt/Eq	1.96	EPS Q/Q	59.70%	Payout	-	Rel Volume	0.17	Prev Close	90.46
Sales Surprise	0.50%	EPS Surprise	7.40%	Sales Q/Q	126.61%	Earnings	Oct 30 BMO	Avg Volume	634.92K	Price	91.36
SMA20	-2.72%	SMA50	-1.20%	SMA200	-5.52%	Trades		Volume	85,596	Change	0.99%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-24	Initiated	JP Morgan	Overweight	$126
Oct-24-24	Initiated	UBS	Neutral	$88
May-14-24	Initiated	Stephens	Overweight	$140
May-06-24	Upgrade	Leerink Partners	Underperform → Market Perform	$50 → $97
Oct-27-23	Upgrade	Oppenheimer	Perform → Outperform	$85
Aug-21-23	Reiterated	Needham	Buy	$65 → $66
Jul-31-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$55 → $82
Jun-05-23	Downgrade	SVB Securities	Market Perform → Underperform	$48 → $43
Jan-03-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$41
Dec-14-22	Initiated	Needham	Buy	$60
Nov-02-22	Downgrade	Oppenheimer	Outperform → Perform
Sep-14-22	Initiated	Berenberg	Buy	$90
Jul-08-22	Initiated	Oppenheimer	Outperform	$80
Jun-27-22	Initiated	Wells Fargo	Underweight	$40
Jun-10-22	Downgrade	Citigroup	Neutral → Sell	$68 → $41
Jun-01-22	Upgrade	Jefferies	Hold → Buy	$88 → $78
Mar-01-22	Initiated	Citigroup	Neutral	$71
Feb-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$82
Jan-25-22	Upgrade	Stifel	Hold → Buy	$120 → $95
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$111

Show Previous Ratings

Dec-18-24 08:00AM	Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-07-24 12:30PM	Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting (PR Newswire)
Nov-29-24 11:31AM	Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-14-24 03:18PM	Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst (Benzinga)
Oct-31-24 03:05AM	Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... (GuruFocus.com)
12:04AM	Loading…
12:04AM	Q3 2024 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-30-24 08:10AM	Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.00%
07:10AM	Blueprint Medicines: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Oct-23-24 10:01AM	Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-21-24 12:00PM	Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-16-24 08:00AM	Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 (PR Newswire)
Oct-15-24 09:55AM	Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know (Zacks)
Sep-10-24 08:00AM	Blueprint Medicines to Present at Upcoming Investor Conferences (PR Newswire)
Aug-19-24 07:00PM	Insider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
09:55AM	Loading…
Aug-09-24 09:55AM	Blueprint Medicines (BPMC) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Aug-02-24 10:44AM	Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat (Zacks)
Aug-01-24 08:05AM	Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -7.40%
07:05AM	Blueprint Medicines: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Jul-25-24 10:02AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-18-24 08:00AM	Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 (PR Newswire)
Jun-25-24 12:39PM	How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park' (Investor's Business Daily)
Jun-07-24 09:15PM	Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Jun-06-24 07:01PM	Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares (GuruFocus.com)
May-30-24 06:01PM	Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT (avapritinib) (PR Newswire) +5.76%
May-23-24 05:05PM	Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 07:50AM	Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target (MT Newswires)
May-06-24 05:32PM	Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing (MT Newswires)
04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
11:45AM	Loading…
11:45AM	Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating (MT Newswires)
07:05AM	Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97 (MT Newswires)
May-03-24 10:03AM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:51AM	Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises (Zacks)
03:05AM	Blueprint Medicines Corp (BPMC) (Q1 2024) Earnings Call Transcript Highlights: Surpassing ... (GuruFocus.com)
May-02-24 09:24PM	Q1 2024 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +12.80%
11:56AM	BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:56AM	Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating (MT Newswires)
10:16AM	Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises (MT Newswires)
08:36AM	Blueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ... (GuruFocus.com)
08:10AM	Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:11AM	Blueprint Medicines: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance (PR Newswire)
Apr-25-24 10:01AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-18-24 08:00AM	Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 (PR Newswire)
Apr-11-24 08:00AM	Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics (PR Newswire)
Apr-04-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-15-24 07:00PM	Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares (GuruFocus.com)
Mar-06-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
11:53AM	Q4 2023 Rigel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-23-24 08:00AM	Blueprint Medicines Highlights AYVAKIT (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting (PR Newswire)
Feb-16-24 03:30PM	Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings (Zacks)
09:37AM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:47AM	Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines (Zacks)
Feb-15-24 10:50PM	Q4 2023 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +14.02%
10:55AM	Blueprint Medicines Surges After Rare-Disease Drug Notches Its Fourth Quarterly Beat (Investor's Business Daily)
08:25AM	Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:43AM	Blueprint Medicines Corp Reports Robust AYVAKIT Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
07:26AM	Blueprint Medicines: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing. (Investor's Business Daily)
07:00AM	Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results (PR Newswire)
Feb-12-24 09:16AM	Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Feb-08-24 10:00AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-01-24 08:00AM	Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 (PR Newswire)
Jan-16-24 12:00PM	What Makes Blueprint Medicines (BPMC) a New Buy Stock (Zacks)
11:51AM	Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now (Zacks)
Jan-09-24 01:51PM	Biotech Is Ripe for M&A. These May Be the Next Acquisition Targets. (Barrons.com)
Jan-08-24 08:00AM	Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-05-24 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-18-23 08:00AM	Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 11:05AM	Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC) (GuruFocus.com)
Dec-12-23 08:05AM	Blueprint Medicines' AYVAKYT (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis (PR Newswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-09-23 12:30PM	Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting (PR Newswire)
Dec-04-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-28-23 08:00AM	Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Blueprint Medicines Corp (GuruFocus.com) +9.97%
Nov-13-23 04:29PM	Oppenheimer Expects the S&P 500s Advance to Continue Into 2024 Heres Why These 2 Stocks Might Be Worth Buying (TipRanks)
Nov-10-23 08:00AM	Blueprint Medicines' AYVAKYT (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis (PR Newswire)
Nov-04-23 03:02AM	Director Jeffrey Albers Sells 10,000 Shares of Blueprint Medicines Corp (GuruFocus.com)
Nov-03-23 04:01PM	Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-31-23 09:55AM	How Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16% (Zacks) +8.32%
09:40AM	Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year? (Zacks)
03:48AM	5 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts (Insider Monkey)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-28-23 01:49PM	Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
07:27AM	Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat (Zacks)
Oct-26-23 11:42PM	Q3 2023 Blueprint Medicines Corp Earnings Call (Thomson Reuters StreetEvents) +25.61%
05:47PM	Why Blueprint Medicines Stock Soared Today (Motley Fool)
09:30AM	Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key Metrics (Zacks)
08:52AM	Blueprint Medicines Corp (BPMC) Reports Q3 2023 Earnings (GuruFocus.com)
08:15AM	Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:09AM	Blueprint Medicines: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Blueprint Medicines Reports Third Quarter 2023 Results (PR Newswire)
Oct-25-23 10:15AM	Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC (Zacks)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire)

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Albers Jeffrey W.	Director	Dec 19 '24	Option Exercise	36.05	15,000	540,750	172,557	Dec 20 04:15 PM
Albers Jeffrey W.	Director	Dec 19 '24	Sale	89.77	15,000	1,346,615	157,557	Dec 20 04:15 PM
Rossi Christina	CHIEF OPERATING OFFICER	Dec 18 '24	Sale	95.91	2,274	218,098	69,383	Dec 20 04:15 PM
Albers Jeffrey W.	Director	Dec 19 '24	Proposed Sale	89.78	15,000	1,346,633		Dec 19 05:17 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 12 '24	Option Exercise	15.01	1,600	24,016	16,786	Dec 16 07:51 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Dec 12 '24	Sale	93.26	1,819	169,636	14,967	Dec 16 07:51 PM
ARIEL HURLEY	Officer	Dec 12 '24	Proposed Sale	94.47	5,022	474,428		Dec 12 04:52 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Nov 29 '24	Sale	96.60	2,353	227,304	150,824	Dec 03 05:33 PM
Rossi Christina	CHIEF OPERATING OFFICER	Nov 27 '24	Sale	95.10	2,274	216,257	71,657	Dec 02 06:52 PM
KATHRYN D HAVILAND	Officer	Nov 29 '24	Proposed Sale	95.10	3,799	361,285		Nov 29 01:40 PM
Christina Rossi and Gregory Pa	Affiliate	Nov 27 '24	Proposed Sale	94.63	9,096	860,754		Nov 27 06:51 PM
COATS LONNEL	Director	Nov 20 '24	Option Exercise	70.75	8,812	623,452	22,066	Nov 22 04:47 PM
COATS LONNEL	Director	Nov 20 '24	Sale	93.77	10,000	937,655	12,066	Nov 22 04:47 PM
COATS LONNEL	Director	Nov 21 '24	Sale	94.87	9,824	932,003	2,242	Nov 22 04:47 PM
LONNEL COATS	Director	Nov 21 '24	Proposed Sale	94.81	9,824	931,413		Nov 21 04:23 PM
LONNEL COATS	Director	Nov 20 '24	Proposed Sale	94.60	10,000	946,000		Nov 20 04:30 PM
Albers Jeffrey W.	Director	Nov 07 '24	Option Exercise	36.05	5,000	180,250	162,557	Nov 12 04:15 PM
Albers Jeffrey W.	Director	Nov 07 '24	Sale	102.00	5,000	510,000	157,557	Nov 12 04:15 PM
Albers Jeffrey W.	Director	Nov 07 '24	Proposed Sale	102.00	5,000	510,000		Nov 07 05:24 PM
Namouni Fouad	PRESIDENT, R & D	Oct 03 '24	Sale	89.32	3,633	324,500	69,070	Oct 04 05:09 PM
Albers Jeffrey W.	Director	Sep 09 '24	Option Exercise	36.05	10,000	360,500	177,259	Sep 11 04:06 PM
Albers Jeffrey W.	Director	Sep 09 '24	Sale	85.57	19,702	1,685,891	157,557	Sep 11 04:06 PM
Albers Jeffrey W.	Director	Sep 09 '24	Proposed Sale	85.57	19,702	1,685,911		Sep 09 09:22 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Aug 15 '24	Sale	95.23	4,409	419,869	67,208	Aug 19 04:00 PM
MICHAEL LANDSITTEL	Officer	Aug 15 '24	Proposed Sale	95.23	4,409	419,891		Aug 15 04:27 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Option Exercise	67.50	41,913	2,828,921	76,642	Aug 07 05:06 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Sale	93.19	41,913	3,905,872	34,729	Aug 07 05:06 PM
Lee Philina	Officer	Aug 05 '24	Proposed Sale	93.00	46,436	4,318,548		Aug 05 04:50 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 03 '24	Option Exercise	54.13	8,817	477,264	52,580	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 05 '24	Option Exercise	54.13	3,850	208,400	47,613	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 03 '24	Sale	111.29	8,817	981,244	43,763	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jul 05 '24	Sale	111.20	3,850	428,120	43,763	Jul 08 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 28 '24	Option Exercise	54.13	333	18,025	44,096	Jul 02 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 28 '24	Sale	111.15	333	37,013	43,763	Jul 02 04:05 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 21 '24	Option Exercise	34.48	60,482	2,085,501	117,797	Jun 25 04:00 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Jun 21 '24	Sale	104.19	74,034	7,713,537	43,763	Jun 25 04:00 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Jun 05 '24	Sale	105.13	4,000	420,520	41,895	Jun 07 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Jun 04 '24	Sale	104.91	2,424	254,302	29,514	Jun 06 04:00 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Jun 03 '24	Sale	106.43	2,436	259,263	45,895	Jun 05 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	May 31 '24	Option Exercise	59.21	24,687	1,461,646	70,968	Jun 04 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	May 31 '24	Sale	105.91	34,108	3,612,480	36,860	Jun 04 04:00 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Jun 03 '24	Sale	106.43	4,922	523,848	31,938	Jun 04 04:00 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 15 '24	Option Exercise	37.69	5,856	220,736	20,769	May 17 04:05 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 15 '24	Sale	106.96	5,856	626,379	14,913	May 17 04:05 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 15 '24	Sale	106.95	3,850	411,772	71,617	May 17 04:05 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 08 '24	Option Exercise	2.32	28,181	65,297	75,467	May 10 04:05 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 02 '24	Option Exercise	36.05	10,000	360,500	57,286	May 06 05:26 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	May 02 '24	Sale	105.00	10,000	1,050,000	47,286	May 06 05:26 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Option Exercise	54.13	1,834	99,274	16,747	May 06 05:19 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	May 02 '24	Sale	103.88	1,834	190,516	14,913	May 06 05:19 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 28 '24	Option Exercise	36.05	5,000	180,250	52,286	Apr 01 04:34 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 28 '24	Sale	95.00	5,000	475,000	47,286	Apr 01 04:34 PM
Albers Jeffrey W.	Director	Mar 07 '24	Sale	90.69	11,033	1,000,583	165,017	Mar 26 09:11 PM
Albers Jeffrey W.	Director	Mar 20 '24	Option Exercise	7.11	25,073	178,287	201,123	Mar 22 05:50 PM
Albers Jeffrey W.	Director	Mar 20 '24	Sale	87.28	25,073	2,188,264	176,050	Mar 22 05:50 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 15 '24	Option Exercise	36.05	5,000	180,250	61,020	Mar 19 05:11 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 15 '24	Sale	87.78	13,734	1,205,606	47,286	Mar 19 05:11 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 15 '24	Option Exercise	15.01	1,600	24,016	18,662	Mar 19 04:48 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 15 '24	Sale	87.76	4,549	399,213	14,913	Mar 19 04:48 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 13 '24	Option Exercise	13.15	1,747	22,975	42,752	Mar 15 04:47 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 13 '24	Sale	90.40	8,023	725,277	34,729	Mar 15 04:47 PM
Hewes L. Becker	CHIEF MEDICAL OFFICER	Mar 07 '24	Sale	90.69	3,097	280,867	46,281	Mar 11 06:29 PM
Durso-Bumpus Debra	CHIEF PEOPLE OFFICER	Mar 07 '24	Sale	90.69	5,093	461,884	57,585	Mar 11 06:28 PM
Haviland Kate	CHIEF EXECUTIVE OFFICER	Mar 07 '24	Sale	90.69	12,464	1,130,360	153,177	Mar 11 06:27 PM
Lee Philina	CHIEF COMMERCIAL OFFICER	Mar 07 '24	Sale	90.69	2,934	266,084	41,005	Mar 11 06:26 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Mar 07 '24	Sale	90.69	2,521	228,629	33,853	Mar 11 06:24 PM
Landsittel Michael	CHIEF FINANCIAL OFFICER	Mar 07 '24	Sale	90.69	5,003	453,722	56,020	Mar 11 06:23 PM
Rossi Christina	CHIEF OPERATING OFFICER	Mar 07 '24	Sale	90.69	6,070	550,488	64,306	Mar 11 06:21 PM
Namouni Fouad	PRESIDENT, R & D	Mar 07 '24	Sale	90.69	4,377	396,950	72,703	Mar 11 06:20 PM
Carter Percy H.	CHIEF SCIENTIFIC OFFICER	Mar 07 '24	Sale	90.69	2,286	207,317	48,331	Mar 11 06:19 PM
McCain Tracey L	EVP AND CHIEF LEGAL OFFICER	Mar 07 '24	Sale	90.69	5,194	471,044	60,498	Mar 11 06:18 PM
Hurley Ariel	PRINCIPAL ACCOUNTING OFFICER	Mar 07 '24	Sale	90.69	1,462	132,589	17,862	Mar 11 06:15 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Mar 04 '24	Sale	93.65	621	58,157	36,374	Mar 06 10:41 AM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Feb 28 '24	Option Exercise	54.13	5,000	270,650	29,495	Mar 01 03:06 PM
Murray Christopher K.	CHIEF TECHNICAL OPERATIONS	Feb 28 '24	Sale	100.00	5,000	500,000	24,495	Mar 01 03:06 PM
Albers Jeffrey W.	Director	Jan 25 '24	Option Exercise	7.13	25,000	178,150	201,050	Jan 29 06:13 PM
Albers Jeffrey W.	Director	Jan 25 '24	Sale	81.91	25,000	2,047,800	176,050	Jan 29 06:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BPMC

Blueprint Medicines Corp

Upgrade your FINVIZ experience